康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09926 康方生物

休市中 06-05 16:09:12

93.600

-5.850

-5.88%

最高103.000	最低93.200	成交量1,949万
今开100.900	昨收99.450	日振幅9.85%
总市值862.06亿	流通市值862.06亿	总股本9.21亿
成交额18.81亿	换手率2.12%	流通股本9.21亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"康方生物","latestPrice":93.6,"timestamp":1780646952008,"preClose":99.45,"halted":0,"volume":19487445,"delay":0,"changeRate":-0.05882352941176479,"floatShares":921000000,"shares":921000000,"eps":-1.232771,"marketStatus":"休市中","change":-5.85,"latestTime":"06-05 16:09:12","open":100.9,"high":103,"low":93.2,"amount":1881391709,"amplitude":0.098542,"askPrice":93.6,"askSize":739000,"bidPrice":93.55,"bidSize":26000,"shortable":3,"etf":0,"ttmEps":-1.37184,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780882200000},"marketStatusCode":7,"adr":0,"listingDate":1587657600000,"exchange":"SEHK","adjPreClose":99.45,"openAndCloseTimeList":[[1780623000000,1780632000000],[1780635600000,1780646400000]],"volumeRatio":0.6410435436127934,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"AKS.HK","impliedVol":0.3736,"impliedVolPercentile":0.0543},"requestUrl":"/m/hq/s/09926","defaultTab":"news","newsList":[{"id":"2641148362","title":"康方新药取得历史性突破，为何蒸发百亿市值","url":"https://stock-news.laohu8.com/highlight/detail?id=2641148362","media":"经济观察网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641148362?lang=zh_cn&edition=full","pubTime":"2026-06-05 19:42","pubTimestamp":1780659720,"startTime":"0","endTime":"0","summary":"6月1日，康方生物开盘后一度涨超12%，然而高开低走，此后三日连续下跌，截至6月5日收盘，康方生物总市值862亿港元，数日内市值跌去超百亿。在康方生物的叙述中，这份登陆ASCO全体会议的临床数据堪称历史性突破。无可辩驳的是，康方生物的HARMONi-6已达到全部预期终点，取得显著阳性。股价为何下跌数据公布后3日，康方生物的市值跌去超百亿港元，截至发稿，总市值已不足千亿。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-06-05/doc-iniakfhq8388122.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-06-05/doc-iniakfhq8388122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00B5MMRT66.SGD","BK1161","BK1574","LU0417516902.SGD","BK4203","LU2488822045.USD","LU2476274720.SGD","09926","HR","IE00BPRC5H50.USD","LU1794554557.SGD","LU0540923850.HKD","LU0348767384.USD","PFS","LU0561508036.HKD","LU0348766576.USD","BK4211","BK4225","LU0417516738.SGD","LU0348735423.USD","LU2778985437.USD","LU0348825331.USD","LU0348827113.USD","LU1720050803.USD","LU0348783233.USD","LU2399975544.HKD","LU2476274308.USD","BK4195","02616","IE00B543WZ88.USD","06978","LU0417516571.SGD","LU0634319403.HKD","LU1961090484.USD","LU0348784397.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169555198","title":"异动解读 | 康方生物盘中大跌5.23%，疑因出现大手卖出交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1169555198","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169555198?lang=zh_cn&edition=full","pubTime":"2026-06-05 15:26","pubTimestamp":1780644409,"startTime":"0","endTime":"0","summary":"康方生物（09926）今日盘中股价出现大幅下跌，跌幅达5.23%，引发市场关注。消息面上，该股票在交易时段内出现一笔大手卖出交易，涉及7.6万股，成交价为95.0港元，涉资约722万港元。此类大额抛售行为通常会对股价造成直接的下行压力，可能是导致本次盘中急跌的主要原因。尽管同一时段有券商发布研报，维持对康方生物“优于大市”的评级，并看好其核心产品依沃西的临床进展与商业化前景，但市场短期交易行为，尤其是大额卖单的出现，似乎主导了股价的走势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105055909","title":"异动解读｜康方生物盘中上涨3.07%，连续回调后技术性反弹叠加多家机构维持买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=1105055909","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105055909?lang=zh_cn&edition=full","pubTime":"2026-06-05 09:31","pubTimestamp":1780623088,"startTime":"0","endTime":"0","summary":"6月5日，康方生物盘中上涨3.07%，报102.6港元，成交额1883.22万港元。该股此前因ASCO大会利好兑现后连续四个交易日下跌，累计跌幅超14%，股价一度跌破100港元整数关口，今日出现技术性反弹。消息面上，近日多家机构密集发布研报维持看好评级：中金给予目标价184港元并维持跑赢行业评级，交银国际维持买入评级目标价175港元，野村将评级上调至买入，中信建投维持买入评级，国信证券维持优于大市评级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640155332","title":"中金：2026 ASCO大会正式闭幕 国产新药闪耀国际学术会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2640155332","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640155332?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:52","pubTimestamp":1780563131,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，本次ASCO大会中国研究数量和质量实现双提升，国产创新药逐渐成为全球FIC/BIC研发核心力量。中金主要观点如下：当地时间6月2日，2026 ASCO大会于美国芝加哥正式闭幕本次大会共94 项中国研究入选口头汇报，其中康方生物HARMONi-6 入选Plenary Session;LBA共13 项，OralAbstract Session、Rapid Abstract Session 等专场入选数量均创历年新高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450110.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1720050803.USD","LU1794554557.SGD","LU2778985437.USD","LU0348767384.USD","LU1961090484.USD","09926","LU2476274720.SGD","LU0348766576.USD","LU0348784397.USD","LU0348827113.USD","LU0417516571.SGD","LU0540923850.HKD","LU2488822045.USD","LU0417516738.SGD","LU0417516902.SGD","LU0348735423.USD","LU0348783233.USD","LU0634319403.HKD","LU2476274308.USD","BK1161","BK1574","LU0561508036.HKD","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU2399975544.HKD","LU0348825331.USD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178555978","title":"康方生物5月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1178555978","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178555978?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:43","pubTimestamp":1780562610,"startTime":"0","endTime":"0","summary":"康方生物科技（开曼）有限公司于2026年6月4日公布了截至2026年5月31日的证券变动月报表。公告显示，公司在本报告期内整体股本状况保持稳定，未发生新的股份发行或回购活动。已发行股本截至5月底为921,143,176股，与上月底持平，且库存股份数仍为0。本月末因购股权行使可能发行股份数为1,059,500股，若全部已授予的购股权行使，可发行或转让股份合计76,217,717股。本公告由董事夏瑜签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640158294","title":"国信证券：维持康方生物(09926)“优于大市”评级 依沃西取得历史性突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2640158294","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640158294?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:01","pubTimestamp":1780560101,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国信证券发布研报称，康方生物的核心产品依沃西在HARMONi-6临床中获得统计学显著且具有临床意义的OS获益，进一步奠定了依沃西在下一代IO治疗中的基石地位。康方生物具备全球化的研发能力，产品的大适应症在国内纳入医保预计将快速放量，维持“优于大市”评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002736","09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640132568","title":"【券商聚焦】中信建投证券维持康方生物(09926)“买入”评级 指其肺癌研究重新定义治疗金标准","url":"https://stock-news.laohu8.com/highlight/detail?id=2640132568","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640132568?lang=zh_cn&edition=full","pubTime":"2026-06-04 14:14","pubTimestamp":1780553653,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券发布研报指，康方生物 于2026 ASCO上发表HARMONi-6研究中期OS分析，结果显著阳性，HR=0.66,成为全球首个在肺癌领域对比PD-1联合化疗取得OS和PFS双显著阳性结果的III期研究，重新定义了sq-NSCLC一线治疗的金标准。报告预计公司2026、2027、2028年营业收入分别为48.22、76.14、106.11亿元，对应增速为57.77%、57.90%、39.36%；归母净利润分别为0.2、10.91、21.44亿元。考虑到公司创新药产品疗效优秀、市场空间广阔，给予“买入”评级。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983028","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132463678","title":"异动解读 | 康方生物盘中大跌5.26%，ASCO利好兑现后回调叠加传闻扰动","url":"https://stock-news.laohu8.com/highlight/detail?id=1132463678","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132463678?lang=zh_cn&edition=full","pubTime":"2026-06-04 10:43","pubTimestamp":1780540992,"startTime":"0","endTime":"0","summary":"康方生物今日盘中股价大跌5.26%，引起市场关注。消息面上，该股延续了在美国临床肿瘤学会（ASCO）年会利好兑现后的持续回调趋势。此前，公司核心产品依沃西联合化疗的HARMONi-6研究在ASCO全体会议上公布了总生存期（OS）阳性结果，但股价在数据公布后冲高回落。市场分析认为，ASCO核心数据披露完毕后，事件驱动型资金选择获利了结。此外，外媒关于美方可能限制对中国生物技术领域投资的相关传闻也对市场短线情绪造成扰动，导致股价承压。尽管股价短线调整，但多家机构仍对公司前景维持看好，并给予了较高的目标价。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124446193","title":"异动解读｜康方生物盘中下跌3.16%，ASCO利好兑现后延续回调股价跌破百元关口","url":"https://stock-news.laohu8.com/highlight/detail?id=1124446193","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124446193?lang=zh_cn&edition=full","pubTime":"2026-06-04 10:22","pubTimestamp":1780539726,"startTime":"0","endTime":"0","summary":"6月4日，康方生物盘中下跌3.16%，报99.45港元，成交额4.18亿港元，股价跌破100港元整数关口。消息面上，该股延续ASCO利好兑现后的持续回调。此前6月1日，公司核心产品依沃西联合化疗HARMONi-6研究在ASCO全体会议公布OS阳性结果，当日股价冲高回落，此后连续三日下跌，累计跌幅超14%。市场分析认为，ASCO核心数据披露完毕后事件驱动型资金获利了结，叠加外媒关于美方可能限制对中国生物技术投资等传闻扰动，短线情绪持续承压。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640353541","title":"康方生物(09926)逆市升1.27% 机构指HARMONI-6中期OS结果显著阳性","url":"https://stock-news.laohu8.com/highlight/detail?id=2640353541","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640353541?lang=zh_cn&edition=full","pubTime":"2026-06-04 09:37","pubTimestamp":1780537024,"startTime":"0","endTime":"0","summary":"金吾财讯 | 康方生物(09926)盘初逆市走高1.27%，最新报104.00港元，成交额364万港元。中信建投新近研究称，康方生物于2026ASCO上发表HARMONi-6研究中期OS分析，结果显著阳性，HR=0.66(P=0.0017)，成为全球首个在肺癌领域对比PD-1联合化疗取得OS和PFS双显著阳性结果的III期研究，重新定义了sq-NSCLC一线治疗的金标准。","market":"nz","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983005","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","LU0417516571.SGD","IE00B543WZ88.USD","LU0348783233.USD","LU0634319403.HKD","LU2476274720.SGD","LU0348825331.USD","LU2399975544.HKD","LU1961090484.USD","LU0348784397.USD","LU0348766576.USD","LU0348767384.USD","09926","LU0348735423.USD","LU2778985437.USD","IE00BPRC5H50.USD","LU0417516902.SGD","LU2476274308.USD","LU0561508036.HKD","LU2488822045.USD","LU1794554557.SGD","LU0417516738.SGD","LU0540923850.HKD","IE00B5MMRT66.SGD","BK1161","LU1720050803.USD","LU0348827113.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640944976","title":"交银国际：维持康方生物(09926)“买入”评级 目标价175港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2640944976","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640944976?lang=zh_cn&edition=full","pubTime":"2026-06-03 13:45","pubTimestamp":1780465508,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研报称，依沃西头对头PD-1单靶在PFS和OS均达到统计学阳性结果，有望重新定义sq-NSCLC一线治疗的金标准、开启全球百亿美元级别的市场潜力。交银国际主要观点如下：HARMONi-6 OS取得超预期的阳性结果依沃西单抗+化疗治疗1L sq-NSCLCIII期HARMONi-6研究的中期OS分析结果在ASCO大会上公布。研究者表示，随着后续数据成熟，中位OS有望进一步延长。综上，该行对HARMONi-3研究依旧持谨慎乐观态度，建议重点关注2H26的最终PFS分析和期中OS分析。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09926","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165712161","title":"异动解读 | 康方生物盘中大跌5.07%，ASCO利好兑现后板块回调资金获利了结","url":"https://stock-news.laohu8.com/highlight/detail?id=1165712161","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165712161?lang=zh_cn&edition=full","pubTime":"2026-06-03 10:31","pubTimestamp":1780453894,"startTime":"0","endTime":"0","summary":"康方生物(09926)今日盘中股价出现大跌，跌幅达5.07%，引起了市场关注。消息面上，此次下跌主要源于其核心产品在ASCO（美国临床肿瘤学会）上公布积极临床数据后，事件驱动型资金选择获利了结。同时，整个生物科技板块今日普遍承压，市场情绪受到外媒关于美方可能限制对中国生物技术投资等传闻的影响，导致短线抛压加剧。此前，康方生物的核心产品依沃西联合化疗的III期研究在ASCO大会上公布了总生存期（OS）的阳性结果，一度推动股价大涨。随着该重大利好事件落地，部分资金选择离场，叠加板块整体走弱，共同导致了股价的显著回调。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160777154","title":"异动解读｜康方生物盘中下跌3.1%，ASCO利好兑现后生物科技板块延续集体回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1160777154","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160777154?lang=zh_cn&edition=full","pubTime":"2026-06-03 09:58","pubTimestamp":1780451894,"startTime":"0","endTime":"0","summary":"消息面上，该股延续ASCO利好兑现后的回调态势。此前6月1日，公司核心产品依沃西联合化疗HARMONi-6研究在ASCO全体会议公布OS阳性结果，死亡风险下降34%，当日股价一度大涨超10%后冲高回落收跌1.86%，成交创历史天量70.4亿港元；6月2日再跌4.49%，盘中出现25万股大手卖出。市场分析认为，ASCO核心数据披露完毕后事件驱动型资金获利了结，叠加外媒报道美方呼吁限制对中国生物技术投资等传闻，短线情绪持续承压。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640445990","title":"中金：维持康方生物(09926)跑赢行业评级 目标价184.0港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2640445990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640445990?lang=zh_cn&edition=full","pubTime":"2026-06-02 14:59","pubTimestamp":1780383566,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持康方生物2026年和2027年盈利预测不变。该行维持跑赢行业评级，基于DCF模型，该行维持目标价184.0港币。HARMONi-6 OS强阳性，重新定义1L肺癌标准治疗方案据公司公告，该临床共入组532例患者，中央型鳞癌占比63%，肿瘤转移占比33.8%，与真实世界患者分布一致。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449010.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09926","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197585310","title":"异动解读｜康方生物盘中下跌4.49%，早盘大手卖出叠加生物科技板块集体回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1197585310","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197585310?lang=zh_cn&edition=full","pubTime":"2026-06-02 09:45","pubTimestamp":1780364711,"startTime":"0","endTime":"0","summary":"6月2日，康方生物盘中下跌4.49%，报108.5港元，成交额9.93亿港元。消息面上，该股早盘出现一笔大手卖出，成交25万股，涉资约2900万港元，对短期市场情绪形成直接冲击。此前6月1日，公司核心产品依沃西联合化疗的III期HARMONi-6研究在ASCO全体会议公布OS阳性结果，死亡风险下降34%，当日股价大涨近10%并获北向资金净买入超27亿港元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199860786","title":"异动解读 | 康方生物盘中大跌5%，疑因早盘出现大手卖出","url":"https://stock-news.laohu8.com/highlight/detail?id=1199860786","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199860786?lang=zh_cn&edition=full","pubTime":"2026-06-02 09:43","pubTimestamp":1780364580,"startTime":"0","endTime":"0","summary":"康方生物今日盘中股价大跌5%，引起了市场关注。消息面上，该股在早盘时段出现一笔大手卖出，成交25万股，涉资约2900万港元，这可能是导致股价承压下跌的直接原因。尽管南向资金近期对该股有净买入操作，但短期内的大额抛售依然对市场情绪造成了冲击，投资者需密切关注后续资金流向。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640968531","title":"多家中国创新药企亮相ASCO：康方生物再迎高光 恒瑞91项研究入选","url":"https://stock-news.laohu8.com/highlight/detail?id=2640968531","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640968531?lang=zh_cn&edition=full","pubTime":"2026-06-01 22:55","pubTimestamp":1780325700,"startTime":"0","endTime":"0","summary":"5月29日至6月2日，2026年美国临床肿瘤学会（ASCO）年会在美国芝加哥召开。作为全球肿瘤领域的顶级学术盛会，国内外众多药企的研究成果以全体大会、口头报告专场、壁报等多种形式亮相ASCO。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606013756390158.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606013756390158.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","LU0417516571.SGD","IE00B543WZ88.USD","LU0348783233.USD","LU0634319403.HKD","LU2476274720.SGD","LU0348825331.USD","LU2399975544.HKD","LU1961090484.USD","LU0348784397.USD","159992","LU0348766576.USD","LU0348767384.USD","09926","LU0348735423.USD","LU2778985437.USD","IE00BPRC5H50.USD","LU0417516902.SGD","06978","LU2476274308.USD","LU0561508036.HKD","LU2488822045.USD","LU1794554557.SGD","LU0417516738.SGD","LU0540923850.HKD","IE00B5MMRT66.SGD","BK1161","LU1720050803.USD","LU0348827113.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640366954","title":"康方生物依沃西再获突破，肺癌死亡风险降低34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640366954","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640366954?lang=zh_cn&edition=full","pubTime":"2026-06-01 20:45","pubTimestamp":1780317900,"startTime":"0","endTime":"0","summary":"康方生物自主研发的全球首创PD-1/VEGF双特异性抗体依沃西，在治疗晚期鳞状非小细胞肺癌的III期临床研究HARMONi-6中取得重大突破。与PD-1抑制剂联合化疗的标准方案相比，依沃西联合化疗可将患者死亡风险降低34%。依沃西组的24个月生存率高达64.7%，对照组为48.6%，生存获益随时间推移持续扩大。在PD-L1阴性患者中，死亡风险降低36%；在伴有肝转移或三个以上转移灶的高危患者中，依沃西同样显示出显著疗效，其中多转移灶患者的死亡风险降低高达53%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-01/doc-inhzxewn3902060.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BPRC5H50.USD","LU2778985437.USD","LU1794554557.SGD","BK1574","LU0348766576.USD","LU0634319403.HKD","LU2399975544.HKD","LU1961090484.USD","LU0348783233.USD","LU0417516738.SGD","IE00B543WZ88.USD","LU0540923850.HKD","LU0417516902.SGD","LU2476274308.USD","LU0348827113.USD","LU0348825331.USD","LU2476274720.SGD","LU0561508036.HKD","09926","LU0417516571.SGD","LU1720050803.USD","LU0348735423.USD","LU0348784397.USD","BK1161","LU0348767384.USD","LU2488822045.USD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640958318","title":"北水动向|北水成交净买入46.57亿 依沃西OS数据战胜PD-1单抗 北水抢筹康方生物(09926)超27亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2640958318","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640958318?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:53","pubTimestamp":1780307587,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，6月1日港股市场，北水成交净买入46.57亿港元。北水净买入最多的个股是康方生物、腾讯、泡泡玛特。港股通(沪)活跃成交股港股通(深)活跃成交股康方生物获净买入27.07亿港元。消息面上，康方生物依沃西在OS数据上战胜PD-1单抗。芯片股出现分化，中芯国际获净买入9604万港元，而华虹半导体遭净卖出2亿港元。此外，长飞光纤光缆获净买入5647万港元，而建滔积层板遭净卖出2.08亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"dbd4a422ef4d87750cf8d9255f6a482f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448568.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2226246903.HKD","IE00BQXX3D17.EUR","LU0067412154.USD","LU2399975544.HKD","IE00B29SXG58.USD","LU0499858602.USD","SG9999018865.SGD","LU0229945570.USD","LU0708995583.HKD","IE00BQXX3C00.GBP","SG9999000327.SGD","HTCD.SI","LU0871576103.HKD","BK1531","LU0823041008.USD","LU1226287875.USD","SG9999004220.SGD","LU0611395673.USD","HK0000320264.USD","LU2362540622.SGD","LU0577902454.USD","LU0049112450.USD","LU1366334578.USD","SG9999014898.SGD","LU1733274473.HKD","600938","LU0672654166.SGD","LU1242518857.USD","LU1868838027.USD","LU0831103253.SGD","LU1883866441.USD","LU2097828557.USD","LU0985320562.USD","LU1366334651.USD","LU1328615791.USD","BK1161","LU0918141705.HKD","LU2125910500.SGD","BK1608","IE0034224299.USD","LU0633140560.USD","LU1046422090.SGD","LU1917777945.USD","BK1095","LU2008162690.USD","LU0456846285.SGD","LU1981816686.USD","LU0061477393.USD","LU0648948544.HKD","BK1224","LU1224709979.USD","LU1725190679.HKD","LU0708995153.HKD","LU0188438112.USD","LU0577902538.SGD","LU0594300179.USD","LU0348816934.USD","BK1618","LU0531971595.HKD","LU1242518931.SGD","LU0640798160.USD","LU0488056044.USD","LU1691799644.USD","LU2087589342.USD","SG9999015978.USD","LU1152091754.HKD","LU0307460666.USD","LU2152927971.USD","LU1769817096.USD","LU1224444064.USD","SG9999001051.SGD","LU1152091168.USD","IE00B0169N27.USD","LU0823038988.USD","LU0890818403.SGD","LU1115378108.SGD","IE00BGV7N243.SGD","LU0823039010.USD","BK1517","IE0003851619.USD","LU0048580855.USD","LU1226288253.USD","LU1629966141.USD","LU0441854154.USD","LU0823413587.USD","LU0675040207.SGD","LU0683595622.HKD","LU1770034418.SGD","LU2039709279.SGD","LU1481107354.HKD","LU0417516571.SGD","LU0320764755.SGD","LU2362541273.HKD","LU1323998911.USD","GB00BDT5M118.USD","LU1956131251.USD","SG9999013353.USD","LU0164880469.USD","LU0823040885.USD","LU0196878994.USD","LU0543330566.HKD","LU0516423091.SGD","IE00B0169L03.USD","LU0516423174.USD","LU0293314216.USD","LU1808992512.USD","LU2237443895.HKD","BK1586","LU1734074674.USD","IE00B067MR52.USD","LU0254981946.USD","IE0001KFT4U8.USD","LU1226287529.USD","LU1515016050.SGD","LU0499858438.USD","LU1008478684.HKD","LU0140636845.USD","LU2148510915.USD","IE0031814852.USD","LU0348783662.USD","SG9999001093.SGD","LU0117841782.USD","LU0320764599.SGD","LU1770036033.HKD","LU0348805143.USD","LU1282649141.HKD","LU0264606111.USD","LU0791590937.USD","LU0449515922.USD","LU1226287792.SGD","LU0127658192.USD","LU0345775950.USD","LU0348814723.USD","LU0786609619.USD","LU2237443622.USD","LU1785774172.SGD","LU0231483743.USD","80883","SG9999001846.SGD","LU0048388663.USD","LU0588545730.USD","LU0979878070.USD","LU0463099449.HKD","LU0070217475.USD","IE00BZ08YR35.GBP","LU1282651048.USD","LU2476274720.SGD","SG9999007991.SGD","LU2279701549.SGD","LU1051768304.USD","LU2317271919.USD","LU0128522157.USD","LU0315178854.USD","LU0345769128.USD","LU0261947096.USD","LU0117844026.USD","IE0009570106.USD","09992","SG9999018857.SGD","SG9999002562.SGD","LU0880133367.SGD","LU1814569148.SGD","LU0898667661.SGD","LU0828237510.HKD","LU1733274390.USD","LU1211504680.USD","LU0164872284.USD","LU0106259558.USD","LU0029874905.USD","LU0588546209.SGD","LU0873338254.USD","00883","LU0173614495.USD","LU0414403682.SGD","LU0607220059.USD","LU2251237488.HKD","LU0417516738.SGD","LU2177674079.SGD","LU0228367735.SGD","BK1589","IE0032431581.USD","LU0192582467.USD","LU2498475776.HKD","LU1226288170.HKD","LU0828238088.HKD","LU2362541513.USD","LU0165289439.USD","LU0163747925.USD","LU2045819591.USD","LU1282651121.HKD","IE00BF5LJ272.USD","LU0175139822.USD","LU0096374516.USD","SG9999002950.SGD","LU1439103000.SGD","LU1960683339.HKD","LU1044875133.USD","BK1528","LU1282649067.USD","SG9999001903.USD","LU0823426308.USD","LU1961090484.USD","LU1993786604.SGD","LU0791591158.USD","LU0348767384.USD","LU1282648689.USD","LU0051755006.USD","LU0359202008.SGD","LU1810669033.SGD","LU0107464264.USD","LU0329678170.USD","IE0008369823.USD","LU0228659784.USD","LU0315179316.USD","LU1880383366.USD","PMRTY","LU0516422440.USD","LU0878004406.USD","IE00BZ08YS42.EUR","IE00BPRC5H50.USD","BK1574","SG9999001689.USD","LU0455707207.USD","LU0328353924.USD","LU0737861772.HKD","LU0605514214.HKD","LU1831875114.USD","LU0886674414.USD","BK1238","HK0000306685.HKD","LU0456842615.SGD","LU1102505929.USD","LU1048588211.SGD","LU1105468828.SGD","LU2237443549.SGD","LU2097828474.EUR","SGXZ90724238.SGD","LU0589944569.HKD","LU0700851271.USD","LU0594300419.USD","LU0149721374.USD","LU2265009873.SGD","SG9999001226.SGD","LU0797268264.HKD","LU0348735423.USD","LU0203347892.USD","LU1044876610.USD","HK0001040168.HKD","LU2778985437.USD","SGXZ86797644.SGD","LU1655091459.SGD","IE00B8L5B284.USD","LU0348783233.USD","LU1196710864.SGD","LU0819121731.USD","LU0348784397.USD","LU1048484197.HKD","LU1196710351.USD","LU0882747503.HKD","LU0029875118.USD","LU2247934214.USD","SG9999014674.SGD","LU0329678337.USD","LU0469268626.HKD","IE00B031J352.USD","LU0823413660.USD","LU0345776255.USD","LU0049853897.USD","LU1023057109.AUD","LU1675838814.USD","LU0572939691.SGD","SGXZ51526630.SGD","BK1609","LU2097828805.USD","LU0541502299.USD","LU1688375341.USD","LU0577902611.USD","LU0348827113.USD","SG9999014914.USD","LU2476274308.USD","LU1196710195.USD","BK1502","LU1794554557.SGD","LU0370786039.SGD","LU0235996351.USD","LU0650527681.SGD","HK0000914660.USD","LU0043850808.USD","LU0143863784.USD","LU0577902298.EUR","LU0084288322.USD","LU1951186391.HKD","IE00B5MMRT66.SGD","SGXZ62798434.SGD","LU0417516902.SGD","LU0054450605.USD","LU0327786744.USD","LU0314109678.HKD","LU2543165471.USD","IE00B543WZ88.USD","LU2449936058.SGD","LU0259732245.USD","LU2462611646.USD","LU2097828714.EUR","LU0261950983.USD","LU0149534421.HKD","LU0211977185.USD","LU2293587155.HKD","LU0651947912.USD","LU0823426480.USD","LU0577902371.SGD","LU2023250504.SGD","LU0531970944.HKD","LU1048596156.SGD","SG9999014880.SGD","LU0039217434.USD","HK0001040143.USD","LU1064131003.USD","IE00B0JY6N72.USD","IE00B031HW06.USD","LU0642271901.SGD","SG9999015945.SGD","LU0738912210.USD","LU0320764243.SGD","LU0080751232.USD","LU1719994722.HKD","00700","LU2237443978.SGD","LU0856984785.SGD","LU0047713382.USD","LU1807302812.USD","LU1282649810.SGD","IE00BZ08YT58.USD","LU0608807433.USD","HK0000320223.HKD","LU1251922891.USD","SGXZ81514606.USD","LU1051769294.HKD","LU1813983027.USD","LU0862451837.USD","LU1044874839.SGD","HK0000914686.HKD","LU0821914370.USD","LU0054237671.USD","LU0169518387.USD","LU2294711473.HKD","LU0164865239.USD","LU0345769631.USD","IE0032834883.USD","LU1328277881.USD","LU2097828631.EUR","LU0210533765.USD","LU0541501648.USD","LU0608807946.USD","LU0633140727.USD","LU2242644610.SGD","TCEHY","LU0588545490.SGD","LU2237443465.HKD","LU0359201612.USD","LU3063872942.SGD","LU1102505762.USD","LU1718418525.SGD","LU0244354667.USD","LU1568876335.HKD","LU0516422366.SGD","SGXZ31699556.SGD","LU1868837722.USD","LU0143863198.USD","IE0003895053.USD","LU2133065610.SGD","LU0348825331.USD","LU0651946864.USD","LU0543330483.HKD","LU2106854487.HKD","BK1521","LU0181495838.USD","LU0823397285.USD","LU0132412106.USD","LU1974910355.USD","LU1504937902.USD","LU0501845795.SGD","LU0918141887.USD","LU0449509016.USD","IE00BQXX3F31.USD","LU0819123356.HKD","LU0052750758.USD","SG9999003461.SGD","LU0210527791.USD","LU0072913022.USD","LU1720050803.USD","SG9999015952.SGD","LU0203345920.USD","LU0214875030.USD","LU1804176565.USD","HK0000352382.USD","LU1568876251.USD","SG9999002463.SGD","LU1868837565.USD","LU0868486357.SGD","IE00B031HY20.USD","LU0828237940.HKD","LU1642822792.SGD","IE0003795394.USD","LU1439102457.SGD","BK1516","LU0593848301.USD","SG9999002828.SGD","LU0251144936.SGD","LU0326948709.USD","LU0348788117.USD","LU0784639295.USD","LU0128522744.USD","LU1188198961.HKD","LU0348766576.USD","LU2251237306.USD","09926","IE00B3M56506.USD","LU0561508036.HKD","SG9999014906.USD","LU0210526637.USD","BK1526","LU0072462343.USD","LU2125910849.SGD","IE00B8HQ1Z84.USD","LU2488822045.USD","LU0588545904.SGD","LU0359201885.HKD","LU0509642566.USD","SG9999017495.SGD","LU1769817179.HKD","HK0000352291.HKD","LU0326950275.SGD","LU0048597586.USD","LU0396098781.USD","LU0516422952.EUR","LU0289960550.SGD","LU1064130708.USD","SG9999015986.USD","LU1880383440.USD","HK0000306701.USD","LU1235295612.USD","IE00B97KM107.HKD","LU0456827905.SGD","LU0572944931.SGD","LU0865486749.SGD","LU0384037296.USD","SG9999000459.SGD","LU1226288097.SGD","LU0106252389.USD","LU0540923850.HKD","LU0823397103.USD","LU0287142896.SGD","LU0862451753.SGD","SG9999000418.SGD","LU0572940350.SGD","LU1316542783.SGD","TCHmain","SG9999001069.SGD","BK1615","BK1591","HK0000151867.HKD","LU0011963245.USD","LU1303224171.USD","SG9999006597.SGD","LU0634319403.HKD","LU0106959298.USD","LU0348723411.USD","LU2257852520.SGD","BK1610","LU2051468812.USD","IE0008368742.USD","LU0737861699.HKD","SGXZ99366536.SGD","LU0269904917.USD","LU2237443382.USD","LU0972618739.USD","IE0008368411.USD","LU0878005551.USD","LU0502904849.HKD","LU0431992006.USD","LU0211331839.USD","SG9999006514.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640936038","title":"招商证券：维持康方生物(09926)“强烈推荐”评级 有望冲击全球肺癌市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2640936038","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640936038?lang=zh_cn&edition=full","pubTime":"2026-06-01 14:48","pubTimestamp":1780296504,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招商证券发布研报称，看好康方生物AK112作为下一代IO治疗基石药物的先发优势和海外价值兑现，此次HARMONi-6展现出的极佳OS获益有望映射到全球，并有望在肺癌这一免疫治疗兵家必争之地率先成功。该行维持盈利预测不变，维持“强烈推荐”投资评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448408.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09926","06099"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akesobio.com","stockEarnings":[{"period":"1week","weight":-0.2075},{"period":"1month","weight":-0.2989},{"period":"3month","weight":-0.1277},{"period":"6month","weight":-0.2458},{"period":"1year","weight":0.1422},{"period":"ytd","weight":-0.1717}],"compareEarnings":[{"period":"1week","weight":-0.0088},{"period":"1month","weight":-0.0478},{"period":"3month","weight":-0.0309},{"period":"6month","weight":-0.0431},{"period":"1year","weight":0.0441},{"period":"ytd","weight":-0.0261}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康方生物科技（开曼）有限公司是一家致力于研究、开发、生产及商业化让全球病人可负担的抗体药的投资控股公司。该公司在研项目涵盖肿瘤、自身免疫及代谢性疾病等多个领域。该公司的产品主要包括有用于肿瘤领域的开坦尼（卡度尼利，PD-1/CTLA-4）、依达方（依沃西，PD-1/VEGF）、莱法利（AK117，CD47）、普络西（AK109，VEGFR-2）、安尼可（派安普利，PD-1）、科泰莱（塔戈利单抗，PD-L1）和用于代谢及自免领域的伊喜宁（伊努西单抗，PCSK9）、爱达罗（依若奇单抗，IL-12/IL-23）、古莫奇单抗（AK111，IL-17）。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.003338},{"month":2,"riseRate":0.333333,"avgChangeRate":0.019031},{"month":3,"riseRate":0.5,"avgChangeRate":0.006875},{"month":4,"riseRate":0.833333,"avgChangeRate":0.041517},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.021305},{"month":6,"riseRate":0.571429,"avgChangeRate":0.084566},{"month":7,"riseRate":0.5,"avgChangeRate":0.087867},{"month":8,"riseRate":0.5,"avgChangeRate":-0.007754},{"month":9,"riseRate":0.5,"avgChangeRate":0.036209},{"month":10,"riseRate":0.5,"avgChangeRate":0.046029},{"month":11,"riseRate":1,"avgChangeRate":0.102206},{"month":12,"riseRate":0.333333,"avgChangeRate":0.028279}],"exchange":"SEHK","name":"康方生物","nameEN":"AKESO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康方生物,09926,康方生物股票,康方生物股票老虎,康方生物股票老虎国际,康方生物行情,康方生物股票行情,康方生物股价,康方生物股市,康方生物股票价格,康方生物股票交易,康方生物股票购买,康方生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}